In addition to modulating the response to DNA damage, both inhibitors of PARP and PRMT5 have been demonstrated to activate innate immune signaling pathways in cancer cells, inducing expression of immune stimulated genes (ISGs) [refs. 61, 62–65]. The gene discussed is PARP1; the disease is cancer.